
Xenetic Biosciences, Inc.
93
Recent developments include research collaborations, clinical trial agreements, preclinical data presentations, a securities shelf filing, and an acquisition announcement to advance the company's therapeutic pipeline.
- Xenetic extended its research collaboration with the University of Virginia [N5].
- The company entered clinical trial services agreements with PeriNess in December 2024 [N6][N7].
- Xenetic presented preclinical data on its DNase platform technology and DNase I with CAR T cells in murine models in late 2024 [N8].
- The company filed a $50 million mixed securities shelf in October 2024 [N8].
- Xenetic reported Q2 losses with mixed revenue results in 2024 and 2025 [N2].
- In September 2026, Xenetic announced plans to acquire Santersus in an all-stock deal to advance its NET-focused pipeline [N8].
Xenetic Biosciences, Inc. operates in the biotechnology sector with a focus on developing novel therapeutics and technologies. The company has a diverse board with expertise in life sciences, finance, and business development. It engages in research collaborations and clinical trial services agreements to advance its pipeline. Financial disclosures indicate ongoing investment in research and development with reported quarterly revenues and net losses. The company has taken steps to raise capital through a securities shelf filing and is pursuing strategic acquisitions to enhance its product offerings.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Xenetic Biosciences, Inc. is a Nasdaq-listed biotechnology company with a board comprising experienced life sciences and business professionals. The company reported Q3 2026 revenue of $725,257 and a net loss of $1,695,478, with a current ratio of 3.15 as of September 30, 2026. Recent business activities include research collaborations, clinical trial agreements, preclinical data presentations, a securities shelf filing, and an acquisition announcement to advance its NET-focused pipeline.
Xenetic's strategic collaborations, clinical trial agreements, and acquisition of Santersus position it to advance its NET-focused therapeutic pipeline. The company's proprietary DNase platform and preclinical data presentations demonstrate scientific progress. The experienced board and management team provide leadership in navigating biotech development and capital markets. The company's liquidity position with a current ratio above 3 suggests capacity to fund near-term operations. These factors collectively support the company's potential to develop innovative therapies addressing unmet medical needs.
Xenetic Biosciences continues to report net losses and negative earnings per share, reflecting ongoing expenses related to research and development without current profitability. The absence of disclosed cash and equivalents in the latest filing may indicate liquidity constraints. The biotechnology sector's inherent risks include clinical trial failures, regulatory hurdles, and competitive pressures. The company's reliance on capital raises, such as the $50 million securities shelf, introduces dilution risk. Execution of strategic acquisitions and collaborations carries integration and operational risks that could impact progress.
Xenetic Biosciences leverages proprietary platform technologies such as DNase-based therapeutics and has established collaborations with academic institutions and clinical service providers. The involvement of experienced board members with scientific and business expertise supports strategic development. The company's focus on NETosis-targeting therapies and novel drug delivery platforms may provide differentiation in the biotechnology market. However, as a development-stage biotech company, its competitive moat depends on successful clinical advancement and commercialization of its pipeline assets.
• Financial Risk: The company reported net losses and negative earnings per share, indicating ongoing funding needs and potential liquidity challenges.
• Clinical and Regulatory Risk: Advancement of pipeline products depends on successful clinical trials and regulatory approvals, which are inherently uncertain.
• Execution Risk: Integration of acquisitions and collaborations requires effective management to realize strategic benefits.
• Market and Competitive Risk: The biotechnology sector is highly competitive with rapid technological changes that may affect the company's market position.
Business trends: The company is actively advancing its therapeutic pipeline through research collaborations, clinical trial agreements, and strategic acquisitions.
Execution milestones: Key milestones include preclinical data presentations, clinical service agreements, securities shelf filings, and acquisition integration.
Key risks: Financial sustainability amid ongoing losses, clinical and regulatory uncertainties, and execution risks related to strategic initiatives.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Xenetic Biosciences, Inc. is a publicly traded company on the Nasdaq Capital Market under ticker XBIO [S1].
- The company is incorporated in Nevada with principal executive offices in Framingham, Massachusetts [S1].
- As of April 17, 2026, the company had 2,291,056 shares outstanding [S1].
- The Board of Directors includes members with extensive experience in life sciences, biotechnology, finance, and business development, including a Nobel laureate in Chemistry [S1].
- The company separates the roles of CEO and Board Chair; the CEO is responsible for strategic direction and day-to-day leadership, while the Board Chair leads the Board's fiduciary duties [S1].
- Xenetic Biosciences reported financial results for the quarter ended September 30, 2026, in a 10-Q filed November 12, 2026 [S2].
- For Q3 2026, the company reported revenue of $725,257 and a net loss of $1,695,478 [S2].
- Basic and diluted earnings per share for Q3 2026 were both -$0.72 [S2].
- As of September 30, 2026, current assets were $6,003,690 and current liabilities were $1,904,046, resulting in a current ratio of 3.15 [S2].
- The company had no reported cash and equivalents or short-term investments disclosed in the latest filing [S2].
- Xenetic has engaged in research collaborations, including an extension with the University of Virginia [N5].
- The company entered clinical trial services agreements with PeriNess in December 2024 [N6][N7].
- Xenetic presented preclinical data on DNase platform technology and DNase I with CAR T cells in murine models in late 2024 [N8].
- The company filed a $50 million mixed securities shelf in October 2024 [N8].
- Recent quarterly reports show losses with some quarters topping revenue expectations and others missing revenue expectations [N2][N8].
- The company announced plans to acquire Santersus in an all-stock deal to advance its NET-focused pipeline in September 2026 [N8].
Generated 2026-11-12
- S1 | 2026-04-24 | 10-K/A
- S2 | 2026-11-12 | 10-Q
- N1 | 2025-10-30 | www.nasdaq.com | Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-beats-q3-earnings-and-revenue-estimates
- N2 | 2025-08-12 | www.nasdaq.com | Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/xenetic-biosciences-xbio-reports-q2-loss-misses-revenue-estimates
- N3 | 2025-04-22 | www.nasdaq.com | USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/usana-health-sciences-usna-q1-earnings-and-revenues-surpass-estimates
- N4 | 2025-03-17 | www.nasdaq.com | XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/xenetic-biosciences-earnings-preview-recent-xbio-insider-trading-hedge-fund-activity-and
- N5 | 2024-12-16 | www.nasdaq.com | Xenetic extends research collaboration with University of Virginia | https://www.nasdaq.com/articles/xenetic-extends-research-collaboration-university-virginia
- N6 | 2024-12-05 | www.nasdaq.com | Xenetic enters clinical trial services agreement with PeriNess | https://www.nasdaq.com/articles/xenetic-enters-clinical-trial-services-agreement-periness
- N7 | 2024-12-05 | www.nasdaq.com | Xenetic enters clinical trial services agreement with PeriNess | https://www.nasdaq.com/articles/xenetic-enters-clinical-trial-services-agreement-periness-0
- N8 | 2024-11-12 | www.nasdaq.com | Progyny (PGNY) Tops Q3 Earnings Estimates | https://www.nasdaq.com/articles/progyny-pgny-tops-q3-earnings-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


